Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: Being younger and getting less benefit from adjuvant tamoxifen treatment

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 12, 2008, Pages 1347-1354

  Yu, Ke Da ^a   Di, Gen Hong ^a   Wu, Jiong ^a   Lu, Jin Song ^a   Shen, Kun Wei ^a   Liu, Guang Yu ^a   Shen, Zhen Zhou ^a   Shao, Zhio Ming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Breast neoplasms; Estrogen receptor; Progesterone receptor; Tamoxifen

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; VINCRISTINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PREMENOPAUSE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; PREMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 54949157337     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0414-2     Document Type: Article

References (20)

1. A Bernoux P de Cremoux C Laine-Bidron EC Martin B Asselain H Magdelenat 1998 Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group Breast Cancer Res Treat 49 219 225
2. WR Bezwoda JD Esser R Dansey I Kessel M Lange 1991 The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen Cancer 68 867 872
3. M Bonetti RD Gelber 2000 A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data Stat Med 19 2595 2609
4. M Borras M Lacroix N Legros G Leclercq 1997 Estrogen receptor-negative/ progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers Cancer Lett 120 23 30
5. X Cui R Schiff G Arpino CK Osborne AV Lee 2005 Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy J Clin Oncol 23 7721 7735
6. MA Fanelli LM Vargas-Roig FE Gago O Tello R Lucero De Angelis DR Ciocca 1996 Estrogen receptors, progesterone receptors, and cell proliferation in human breast cancer Breast Cancer Res Treat 37 217 228
7. A Goldhirsch JH Glick RD Gelber AS Coates B Thurlimann HJ Senn 2005 Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 16 1569 1583
8. VR Grann AB Troxel NJ Zojwalla JS Jacobson D Hershman AI Neugut 2005 Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma Cancer 103 2241 2251
9. W Jonat KI Pritchard R Sainsbury JG Klijn 2006 Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient J Cancer Res Clin Oncol 132 275 286
10. AA Keshgegian 1994 Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors. Arch Pathol Lab Med 118 240 244
11. AA Keshgegian A Cnaan 1996 Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome Arch Pathol Lab Med 120 970 973
12. J Kiani A Khan H Khawar F Shuaib S Pervez 2006 Estrogen receptor alpha-negative and progesterone receptor-positive breast cancer: lab error or real entity? Pathol Oncol Res 12 223 227
13. L Levine 2003 Tamoxifen stimulates arachidonic acid release from rat liver cells by an estrogen receptor-independent, non-genomic mechanism BMC Cancer 3 24
14. D Nikolic-Vukosavljevic K Kanjer Z Neskovic-Konstantinovic D Vukotic 2002 Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer Int J Biol Markers 17 196 200
15. CK Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med 339 1609 1618
16. CK Osborne 1998 Steroid hormone receptors in breast cancer management Breast Cancer Res Treat 51 227 238
17. A Shimada S Kimura K Abe K Nagasaki I Adachi K Yamaguchi M Suzuki T Nakajima LS Miller 1985 Immunocytochemical staining of estrogen receptor in paraffin sections of human breast cancer by use of monoclonal antibody: comparison with that in frozen sections Proc Natl Acad Sci USA 82 4803 4807
18. EP Winer C Hudis HJ Burstein AC Wolff KI Pritchard JN Ingle RT Chlebowski R Gelber SB Edge J Gralow MA Cobleigh EP Mamounas LJ Goldstein TJ Whelan TJ Powles J Bryant C Perkins J Perotti S Braun AS Langer GP Browman MR Somerfield 2005 American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004 J Clin Oncol 23 619 629
19. KD Yu GH Di J Wu JS Lu KW Shen ZZ Shen ZM Shao 2007 Development and trends of Surgical Modalities for Breast Cancer in China: a review of 16-year data Ann Surg Oncol 14 2502 2509
20. KD Yu GY Liu GH Di J Wu JS Lu KW Shen ZZ Shen ZM Shao 2007 Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients Breast 16 307 315